Kaelin Says Genetics Could Turn Cancer Into a Chronic Disease

Nobel laureate William Kaelin says advances in cancer genetics are opening more targets for treatment and could help make cancer manageable like a chronic disease. He made the remarks in an early-2026 interview in Dubai, where he pointed to precision therapies, combination treatments and faster drug discovery as the next steps.

Why it matters: - William Kaelin says cancer genetics is moving more tumors from untreatable to treatable. - Kaelin argues that precision therapies and combination regimens could help blunt drug resistance, a major reason cancers relapse or stop responding. - The shift matters because cancer treatment has already moved from broad chemotherapy toward targeted and precision medicine, and genetics may push that transition further.

What happened: - In early 2026 in Dubai, United Arab Emirates, Kaelin spoke exclusively with reporters from Southern Finance and 21st Century Business Herald. - Kaelin is the 2019 Nobel Prize laureate in Physiology or Medicine. - Kaelin said deeper understanding of cancer’s genetic mechanisms is driving major advances in drug development. - Kaelin said more targets once considered "undruggable" are now becoming treatable.

The details: - Kaelin spent four decades researching how cells sense oxygen. - His work identified the central role of the VHL protein in regulating hypoxia-inducible factors. - That research helped explain how organisms adapt to low-oxygen environments. - The same scientific foundation contributed to the cancer drug belzutifan. - The U.S. Food and Drug Administration approved belzutifan for certain cancers associated with von Hippel–Lindau disease, including kidney cancer. - Kaelin received the Nobel Prize for the landmark discovery. - Kaelin’s wife had died of breast cancer four years before he received the award. - On the night the Nobel Prize was announced, Kaelin shared a photograph of himself with his late wife and said, in effect, that the honor belonged to both of them and to the fight against cancer they shared.

Between the lines: - The interview reflects a broader scientific view that cancer is becoming more tractable as genomics sharpens the search for drug targets. - Artificial intelligence is also improving drug discovery efficiency, which could shorten the path from lab research to clinical use. - The article frames cancer not as a single breakthrough problem but as a disease that may become increasingly manageable through layered scientific progress.

What's next: - Kaelin expects future gains to come from pairing genetics-driven target discovery with combination treatments. - Continued progress will depend on tighter links between academia, industry and clinical practice. - The article leaves open a broader question: how long it will take for cancer to become truly controllable at scale.